David Nierengarten

Sep 16, 2026

David Nierengarten rated COGT as Outperform on Sep 16, 2026, setting a price target of 55. Shares have remained stable near 31.5, leaving the 55 target still in play.

Sep 16, 2026

On Sep 16, 2026, NUVB was given a Outperform rating by David Nierengarten, with a target price of 11. The stock traded sideways with a 1.21% move, keeping the bullish thesis unresolved.

Sep 15, 2026

SRRK received a Outperform rating from David Nierengarten on Sep 15, 2026, aiming for 70. The rating hasn’t played out as hoped, with the stock trading 6.70% below expectations.

Sep 15, 2026

On Sep 15, 2026, David Nierengarten published a Outperform outlook on CATX, with a target of 11. Shares gained 5.49%, underscoring the accuracy of the bullish outlook toward 11.

Sep 14, 2026

David Nierengarten on Sep 14, 2026 assigned TLX a Outperform rating, with a price target of 22. The Buy call aligned well with market performance, producing a gain of 6.88%.

Sep 10, 2026

On Sep 10, 2026, David Nierengarten reaffirmed IRON with a Outperform rating, targeting 100. Shares slid 6.22% despite the recommendation, highlighting downside risks.

Aug 19, 2026

On Aug 19, 2026, David Nierengarten initiated coverage on AKTS with a Outperform rating and target of 35. The Buy call has yet to be validated as shares remain 13.12 away from the target.

Aug 05, 2026

David Nierengarten issued a Outperform recommendation for SYRE on Aug 05, 2026, price target set at 130. The market hasn’t rewarded the bullish outlook, exposing uncertainty in the call.

Jul 30, 2026

On Jul 30, 2026, XNCR was evaluated by David Nierengarten, who gave a Outperform rating and target of 26. This case illustrates how a timely bullish rating can translate into tangible gains of 15.03%.

Jul 30, 2026

David Nierengarten rated DMRA as Outperform on Jul 30, 2026, setting a price target of 40. The stock has underperformed, dropping 22.66% despite the bullish target of 40.

Jul 29, 2026

On Jul 29, 2026, KNSA was given a Outperform rating by David Nierengarten, with a target price of 99. The stock traded sideways with a -4.55% move, keeping the bullish thesis unresolved.

Jul 28, 2026

ARGX received a Outperform rating from David Nierengarten on Jul 28, 2026, aiming for 1050. Momentum has favored the Buy call, with shares climbing from 990.32 to 990.32, rewarding those who trusted the recommendation.

Jul 21, 2026

David Nierengarten on Jul 21, 2026 assigned IMNM a Outperform rating, with a price target of 31. The Buy call aligned well with market performance, producing a gain of 5.22%.

Jul 13, 2026

On Jul 13, 2026, David Nierengarten reaffirmed COAG with a Outperform rating, targeting 55. Market indecision has kept the 55 target in a holding pattern.

Jun 02, 2026

David Nierengarten rated ODTX as Outperform on Jun 02, 2026, setting a price target of 30. Shares have remained stable near 24.38, leaving the 30 target still in play.

May 15, 2026

On May 15, 2026, STRO was given a Outperform rating by David Nierengarten, with a target price of 60. Despite the Buy call, shares fell from 15.34 to 15.34, challenging the optimistic stance.

May 08, 2026

STTK received a Outperform rating from David Nierengarten on May 08, 2026, aiming for 11. The rating hasn’t played out as hoped, with the stock trading 12.26% below expectations.

Apr 16, 2026

On Apr 16, 2026, David Nierengarten published a Outperform outlook on FENC, with a target of 13. Shares gained 68.57%, underscoring the accuracy of the bullish outlook toward 13.

Apr 01, 2026

David Nierengarten on Apr 01, 2026 assigned ORIC a Outperform rating, with a price target of 17. The Buy call aligned well with market performance, producing a gain of 70.99%.

Mar 31, 2026

On Mar 31, 2026, David Nierengarten reaffirmed BCAX with a Outperform rating, targeting 30. The recommendation was supported by strong follow-through as the stock rose from 22.64 to 22.64.

Feb 25, 2026

BEAM was rated Outperform by David Nierengarten on Feb 25, 2026, with a price objective of 65. This case shows how bullish projections can fail, with the stock now below 24.95.

Dec 16, 2025

On Dec 16, 2025, David Nierengarten initiated coverage on GBIO with a Outperform rating and target of 7. Neutral price movement of -0.74% leaves room for interpretation.

Dec 11, 2025

David Nierengarten issued a Outperform recommendation for BBOT on Dec 11, 2025, price target set at 25. The market hasn’t rewarded the bullish outlook, exposing uncertainty in the call.

Oct 27, 2025

On Oct 27, 2025, FATE was evaluated by David Nierengarten, who gave a Outperform rating and target of 7. This case illustrates how a timely bullish rating can translate into tangible gains of 63.23%.

Oct 15, 2025

David Nierengarten rated ANAB as Outperform on Oct 15, 2025, setting a price target of 70. The call has proven timely, with shares rising 60.98% toward the price target of 70.

Feb 12, 2025

On Feb 12, 2025, David Nierengarten published a Outperform outlook on SWTX, with a target of 77. Market action contradicted the Buy thesis, as shares slipped to 46.99.

Jan 13, 2025

David Nierengarten on Jan 13, 2025 assigned BPMC a Outperform rating, with a price target of 124. The Buy call aligned well with market performance, producing a gain of 25.25%.

Nov 18, 2024

On Nov 18, 2024, David Nierengarten reaffirmed CMRX with a Outperform rating, targeting 6. The recommendation was supported by strong follow-through as the stock rose from 8.54 to 8.54.

Sep 30, 2024

INZY was rated Outperform by David Nierengarten on Sep 30, 2024, with a price objective of 15. This case shows how bullish projections can fail, with the stock now below 4.

Apr 23, 2024

David Nierengarten issued a Outperform recommendation for PRME on Apr 23, 2024, price target set at 12. The market hasn’t rewarded the bullish outlook, exposing uncertainty in the call.